Header Logo

Connection

QIULING SHI to Female

Back to Details
This is a "connection" page, showing publications QIULING SHI has written about Female.
QIULING SHI
Connection Strength
0.346
Female
  1. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017 06; 158(6):1108-1112.
    View in: PubMed
    Score: 0.017
  2. Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer. 2016 11; 67:83-90.
    View in: PubMed
    Score: 0.016
  3. Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. J Pain Symptom Manage. 2016 12; 52(6):822-831.
    View in: PubMed
    Score: 0.016
  4. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.
    View in: PubMed
    Score: 0.014
  5. Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J Investig Dermatol Symp Proc. 2013 Dec; 16(1):S49-50.
    View in: PubMed
    Score: 0.013
  6. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res. 2013 Nov; 22(9):2331-9.
    View in: PubMed
    Score: 0.013
  7. Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain. 2013 Mar; 14(3):290-6.
    View in: PubMed
    Score: 0.013
  8. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2011 Jun 15; 117(12):2779-90.
    View in: PubMed
    Score: 0.011
  9. Does recall period have an effect on cancer patients' ratings of the severity of multiple symptoms? J Pain Symptom Manage. 2010 Aug; 40(2):191-9.
    View in: PubMed
    Score: 0.011
  10. Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage. 2009 Feb; 37(2):168-74.
    View in: PubMed
    Score: 0.009
  11. People in pain: how do they seek relief? J Pain. 2007 Aug; 8(8):624-36.
    View in: PubMed
    Score: 0.009
  12. Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenet Genomics. 2005 Aug; 15(8):547-55.
    View in: PubMed
    Score: 0.008
  13. Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1477-84.
    View in: PubMed
    Score: 0.007
  14. Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis. 2004 Sep; 25(9):1695-700.
    View in: PubMed
    Score: 0.007
  15. [Genetic susceptibility to intermediate myasthenia syndrome following organophosphate insecticides poisoning]. Zhonghua Yu Fang Yi Xue Za Zhi. 2003 Jul; 37(4):259-62.
    View in: PubMed
    Score: 0.007
  16. Patient-reported symptoms at discharge and risk of complications after gynecologic surgery. Int J Gynecol Cancer. 2023 02 06; 33(2):271-277.
    View in: PubMed
    Score: 0.006
  17. Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecol Oncol. 2021 04; 161(1):83-88.
    View in: PubMed
    Score: 0.006
  18. Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. Int J Gynecol Cancer. 2021 01; 31(1):114-121.
    View in: PubMed
    Score: 0.005
  19. [Study on family aggregation of esophageal cancer in Linzhou city]. Zhonghua Yu Fang Yi Xue Za Zhi. 2000 Sep; 34(5):269-70.
    View in: PubMed
    Score: 0.005
  20. A prospective randomized trial comparing liposomal bupivacaine vs standard bupivacaine wound infiltration in open gynecologic surgery on an enhanced recovery pathway. Am J Obstet Gynecol. 2021 01; 224(1):70.e1-70.e11.
    View in: PubMed
    Score: 0.005
  21. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160.
    View in: PubMed
    Score: 0.005
  22. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2021 Jan; 29(1):467-475.
    View in: PubMed
    Score: 0.005
  23. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107.
    View in: PubMed
    Score: 0.005
  24. Severe Preoperative Symptoms Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection. Ann Surg Oncol. 2019 Dec; 26(13):4548-4555.
    View in: PubMed
    Score: 0.005
  25. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019 10; 58(4):662-671.
    View in: PubMed
    Score: 0.005
  26. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
    View in: PubMed
    Score: 0.005
  27. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol. 2019 03; 152(3):492-500.
    View in: PubMed
    Score: 0.005
  28. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
    View in: PubMed
    Score: 0.005
  29. Assessment of baseline symptom burden in treatment-na?ve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447.
    View in: PubMed
    Score: 0.005
  30. Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngol Head Neck Surg. 2018 11 01; 144(11):1066-1076.
    View in: PubMed
    Score: 0.005
  31. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
    View in: PubMed
    Score: 0.005
  32. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. Obstet Gynecol. 2018 08; 132(2):281-290.
    View in: PubMed
    Score: 0.005
  33. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250.
    View in: PubMed
    Score: 0.005
  34. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
    View in: PubMed
    Score: 0.005
  35. Validation and Application of the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM). J Natl Cancer Inst Monogr. 2017 11 01; 2017(52).
    View in: PubMed
    Score: 0.004
  36. A Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-controlled Analgesia After Major Hepatopancreatobiliary Surgery. Ann Surg. 2017 09; 266(3):545-554.
    View in: PubMed
    Score: 0.004
  37. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.004
  38. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1107-14.
    View in: PubMed
    Score: 0.004
  39. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.
    View in: PubMed
    Score: 0.004
  40. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.004
  41. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
    View in: PubMed
    Score: 0.004
  42. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43.
    View in: PubMed
    Score: 0.004
  43. Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg. 2015 Sep; 150(3):613-9.e2.
    View in: PubMed
    Score: 0.004
  44. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol. 2015 Mar; 136(3):440-5.
    View in: PubMed
    Score: 0.004
  45. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.
    View in: PubMed
    Score: 0.004
  46. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
    View in: PubMed
    Score: 0.003
  47. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul; 26(5):699-705.
    View in: PubMed
    Score: 0.003
  48. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct; 11(5):587-99.
    View in: PubMed
    Score: 0.003
  49. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol. 2011 Mar 10; 29(8):994-1000.
    View in: PubMed
    Score: 0.003
  50. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
    View in: PubMed
    Score: 0.003
  51. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010 Jan 01; 116(1):137-45.
    View in: PubMed
    Score: 0.003
  52. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Oct 15; 113(8):2102-9.
    View in: PubMed
    Score: 0.002
  53. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: a case-control analysis. Lung Cancer. 2007 Aug; 57(2):143-51.
    View in: PubMed
    Score: 0.002
  54. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis. 2007 Jul; 28(7):1430-6.
    View in: PubMed
    Score: 0.002
  55. Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Pharmacogenet Genomics. 2005 Aug; 15(8):557-64.
    View in: PubMed
    Score: 0.002
  56. Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Int J Cancer. 2005 May 20; 115(1):131-6.
    View in: PubMed
    Score: 0.002
  57. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005 Sep; 26(9):1596-602.
    View in: PubMed
    Score: 0.002
  58. Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2005 May; 14(5):1188-93.
    View in: PubMed
    Score: 0.002
  59. Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004 Dec 01; 10(23):7903-10.
    View in: PubMed
    Score: 0.002
  60. No Association between hOGG1 Ser326Cys polymorphism and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1081-3.
    View in: PubMed
    Score: 0.002
  61. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003 Sep; 24(9):1499-503.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.